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Colon cancer prevention currently relies on colonoscopy using 
white light to detect and remove polyps, but small and flat 
polyps are difficult to detect and frequently missed when using 
this technique. Fluorescence colonoscopy combined with a 
fluorescent probe specific for a polyp biomarker may improve 
polyp detection. Here we describe GE-137, a water-soluble 
probe consisting of a 26–amino acid cyclic peptide that binds 
the human tyrosine kinase c-Met conjugated to a fluorescent 
cyanine dye. Intravenous administration of GE-137 leads to 
its accumulation specifically in c-Met–expressing tumors in 
mice, and it is safe and well tolerated in humans. Fluorescence 
colonoscopy in patients receiving intravenous GE-137 enabled 
visualization of all neoplastic polyps that were visible with 
white light (38), as well as an additional nine polyps that were 
not visible with white light. This first-in-human pilot study 
shows that molecular imaging using an intravenous fluorescent 
agent specific for c-Met is feasible and safe, and that it may 
enable the detection of polyps missed by other techniques.
Colorectal cancer (CRC) is a major cause of cancer death1, and 
colonoscopy is firmly established as the mainstay of CRC prevention. 
Evidence that CRC can be prevented by the removal of polyps is 
strong, especially for cancers of the left colon2. However, colonoscopy 
using current techniques only provides partial protection overall and 
limited, if any, protection in the right colon3,4. Although the aggressive 
biology of some cancers may in part explain this lack of complete 
protection, it is likely that limitations in polyp detection using current 
techniques are primarily responsible5.
Technical aspects of endoscopic imaging have a major role in deter-
mining polyp detection rates, together with human factors such as the 
quality of bowel preparation and the skill of the endoscopist6. Imaging 
at colonoscopy is currently performed using white light (WL), and 
polyps are detected by operators who are trained to discriminate 
polyps from normal colon by recognizing characteristics such as 
protrusion into the lumen and mucosal color changes. However, 
these features are less discriminatory in smaller and non-polypoid 
lesions, leading to miss rates of up to 25% (ref. 7). Combining tar-
geted molecular probes and advanced imaging technology could 
improve polyp detection. Several biomarkers and detection systems 
have shown promise in preclinical trials8,9, but only topically applied 
agents have thus far been tested in humans10,11. These agents suffer 
from the major disadvantage that application to the whole surface 
area of the colon is seldom achievable.
c-Met overexpression has been shown to occur as an early event in 
the colorectal adenoma-carcinoma sequence12 making it a suitable 
biomarker for colorectal neoplasia13. In addition, its expression on 
the cell membrane makes extracellular epitopes accessible for tar-
geting with fluorescent imaging agents. Here we report our initial 
experiences with fluorescence-guided colonoscopy using the imaging 
agent GE-137 (European Clinical Trials Database registration number 
2010-019197-33; publicly accessible via the CCMO register (https://
www.toetsingonline.nl/to/ccmo_search.nsf/Searchform?OpenForm). 
GE-137 is a water-soluble 26–amino acid cyclic peptide labeled with a 
proprietary cyanine dye (λmax ex = 648 nm) with a high affinity (Kd = 2 nM) 
for human c-Met. We describe the stages of development of GE-137, 
as well as its safety, pharmacokinetics and imaging characteristics in 
healthy volunteers and patients at high risk of colorectal neoplasia, 
in conjunction with a customized colonoscopy imaging system. 
Because there is currently no commercially available colonoscope 
with the ability to detect both WL and near-infrared (NIR) fluorescent 
light, we developed a custom-built dual WL and fluorescent light (FL) 
endoscopic imaging system specifically for this project.
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RESULTS
Generation of a fluorescent c-Met binding probe
The water-soluble 26–amino acid cyclic peptide component of the 
probe was selected from an M-13 phage-display library on the basis of 
its high affinity for the extracellular domain of human c-Met, its lack 
of competition with hepatocyte growth factor (HGF)14 and its lack 
of effect on HGF-stimulated proliferation in vitro (data not shown). 
We then conjugated this peptide (AGSCYCSGPPRFECWCYETEGT) 
with a linker peptide (GGGK) and subsequently to a modified 
Cy5 dye (Cy5**) to yield GE-137 (AGSCYCSGPPRFECWCYETEGT-
GGGK-Cy5** (Fig. 1a)). This particular Cy5 derivative was selected 
from four cyanine dyes (Supplementary Fig. 1) on the basis of its 
improved brightness, resistance to photobleaching and low degree of 
binding to plasma proteins compared to the other dyes tested (data 
not shown). The fluorescence absorbance and emission spectra for 
GE-137 are shown in Figure 1b. The affinity of GE-137 for human 
c-Met was determined in vitro using a fluorescence polarization assay: 
Kd = 3 nM (± 0.5) (Fig. 1c).
Lyophilized (dry) GE-137 has a documented shelf life of 12 months 
when stored at 2–8 °C. The chemical and physical stability of the 
reconstituted product (in solution) has been demonstrated for 24 h 
at 2–8 °C (Supplementary Table 1). Furthermore, the compound 






































































































































Figure 1 GE-137 chemical and optical properties and testing in a rodent model of colon cancer. (a) Chemical structure of the probe. (b) Fluorescence 
absorbance and emission spectra of the probe. (c) Fluorescence polarization analysis demonstrating binding of the contrast agent (black squares) to 
cMet with a Kd of ~3 nM (±0.5). The scrambled peptide control (white circles) showed no binding in the concentration range tested (0–150 nM).  
(d,e) Representative fluorescence scanned cryosections of whole tumor bearing nude mice at various time points after injection of Cy5**-labeled 
scrambled peptide control (d) or GE-137 (e). The arrows indicate the tumor locations. A non-injected control was also included (d, leftmost 
cryosection). The time points after injection were, from left to right, 5, 60, 120 and 240 min, respectively. Scale bar, 1 cm. Images are displayed on 
a linear ‘negative’ gray scale in which black indicates high fluorescence signal. (f,g) Graphs to show the results of quantification of the fluorescence 
(expressed as a percentage of the injected dose per gram of tissue (%ID/g)) in blood and homogenates of liver and tumor tissue at 5, 30, 60, 120  
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is photostable under ambient light conditions for several hours and 
is not substantially bleached by intense light exposure even after 
several minutes (the fluorescence half-life is 7 min in tissue sam-
ples illuminated under worst-scenario conditions (300 mW cm−2)) 
(Supplementary Fig. 2).
Preclinical efficacy studies
The quantitative biodistribution, pharmacokinetics, binding spe-
cificity and qualitative fluorescence of GE-137 were assessed in a 
xenograft mouse model of CRC using subcutaneous injection of the 
c-Met–expressing human CRC cell line HT29. Cryosections of whole 
mice were made and fluorescence scans performed using a method 
we have described previously15. Intravenously administered GE-137 
accumulates in the c-Met–expressing tumor xenografts and washes 
out of other tissues to leave a fluorescent signal in the tumors and 
kidneys 120 and 240 min after injection, whereas the Cy5**-labeled 
scrambled peptide control is only visible in the kidneys (Fig. 1d,e). 
Fluorescence pharmokinetics and qualitative fluorescence imaging 
were performed in vivo (Supplementary Fig. 3a,b). Co-administra-
tion of GE-137 together with an excess of unlabeled peptide led to a 
reduction in tumor uptake of the agent (Supplementary Fig. 3c,d). 
In the same mouse model, the quantitative biodistribution of the 
probe was measured in blood and homogenates of the liver, kidney, 
muscle and c-Met–expressing tumor xenografts at 5, 30, 60, 120 and 
240 min after intravenous administration of GE-137 or the control 
(Fig. 1f,g). GE-137 accumulates in the c-Met–expressing tumor 
xenografts, whereas the labeled scrambled peptide control does 
not. Further in-vivo fluorescence imaging was performed in a sec-
ond mouse model designed to more closely replicate the clinical 
situation. In the first mouse model, large spherical subcutaneously 
xenografted tumors were imaged against a background of muscle that 
doesn’t express c-Met. In the clinical situation, small flat polyps must 
be detected against a background of normal colon, which expresses 
c-Met at low levels and may have fecal remnants with native fluores-
cence. Therefore, in the second mouse model, subcutaneous HT-29 
and HCT-15 tumor xenografts from mice injected with GE-137 or a 
labeled scrambled peptide control were surgically removed and thin 
slices of the tumor were imaged against a background of surgically 
opened normal mouse colon. The tumor-to-colon ratio of fluores-
cence was measured and images were assessed by blinded observ-
ers (Supplementary Fig. 4). These preclinical studies suggest that 
GE-137 accumulates specifically in human c-Met–expressing color-
ectal tumors and that GE-137 at a dose of 0.18 mg kg−1 will provide 
sufficient contrast to enable c-Met–rich lesion detection against a 
background of normal colon in humans.
Safety studies
The probe was extensively tested for safety with in vitro genotoxicity 
and phototoxicity studies. Biodistribution, pharmacology and general 
toxicity studies were performed in rats and cynomolgus monkeys in 
single-dose and repeat-dose studies. Specific toxicity was investigated 
with genotoxicity tests, spermatogenesis evaluation and cardiovascular 
toxicity testing in cynomolgus monkeys. No adverse effects were seen 
in any of these studies (data not shown). When the no observed adverse 
effect level (NOAEL) was expressed as human equivalent dose on the 
basis of body surface area, this corresponded to 15.5 mg kg−1. This 
suggested that a single intravenous (i.v.) dose of up to 0.36 mg kg−1, 
(twice the expected efficacious clinical imaging dose) would be 
well tolerated in humans. A single i.v. administration of GE-137 
(0.02–0.18 mg kg−1) was well tolerated and seemed to be safe in both 
healthy volunteers and subjects at high risk of colorectal neoplasia 
(total n = 31) (Supplementary Table 2).
The optimal dose and optimal time interval between GE-137 
administration and endoscopy, or optimal imaging time point, 
was estimated by performing colon wall fluorescence measure-
ments (Fig. 2a) in healthy volunteers at repeated sigmoidoscopy 
using a prototype fluorescence colonoscope (Fig. 2b,c) after GE-137 
administration. The background clearance half-life was calculated 
from these measurements and was ~2 h 30 min at all doses (data 
not shown). The optimal imaging time point (3 h) was determined 
by adding the time to peak-signal (30 min (data not shown)) to 
one background clearance half-life. The intensity and uniformity 
of the texture of colon wall fluorescence observed were higher than 
expected from the preclinical model (data not shown). It was there-
fore estimated that a dose reduction to 70% of the optimal imaging 
dose calculated from the preclinical models (from 0.18 mg kg−1 to 
0.13 mg kg−1) would be optimal for imaging subjects with a high 
suspicion of CRC.
GE-137 is renally cleared, and the exposure derived from area under 
the curve (AUC) data was dose-linear (Supplementary Fig. 5). The 
clearance rate was approximately 0.13 l kg−1 hr−1 and comparable 
between dose groups. At a dose of 0.13 mg kg−1, the observed plasma 
concentrations were 0.12–0.16 mg l−1 at 3 h after administration.
a b
c
Figure 2 Experimental system for combined WL and NIR fluorescence 
colonoscopy in humans. (a) Fluorescence image showing the method of 
estimation of colonic wall background fluorescence. A fluorescent probe 
standard inserted via the working channel of the endoscope (indicated 
with an arrow) is shown approximated to the colonic wall (see methods). 
(b) Screenshot of the simultaneous WL and FL endoscopic images as 
seen on the monitor during endoscopy. (c) The customized fluorescence 
colonoscopy system. The standard fiber-colonoscope is shown attached via 
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Pilot study in patients
In 15 patients at high risk of colorectal neo-
plasia a total of 101 lesions were detected; 
were detected during first-pass inspection 
with WL, and an additional 22 were detected during second-pass 
inspection with dual WL/FL. Of these, 17 were only visible using FL 
imaging (Fig. 3 and Supplementary Table 3). The additional lesions 
detected with FL tended to be small (<6 mm) and have non-polypoid 
morphology (Fig. 3e,f).
Fluorescence relative to background was assessed during the live 
imaging for all the 101 lesions described above as well as the areas 
selected for additional biopsies from normal mucosa. Fluorescence was 
clearer in a dynamic real-time setting (Supplementary Videos 1–4) 
than it is in a still image. Most normal mucosa showed background 
fluorescence, whereas most adenomas had clearly increased fluores-
cence and none displayed background levels of fluorescence (Fig. 3g) 
The majority of hyperplastic polyps had increased fluorescence. The 
proportion of lesions from each histological category with increased 
fluorescence over background was adenoma 100% (47/47), hyper-
plastic polyp 78% (33/42) and normal histology 19% (8/41). Overall, 
fluorescence findings in vivo were highly significantly associated with 
the histology (Fig. 3g, P = 0.00003, Fisher’s exact test). Fluorescence 
is also significantly associated with c-Met expression, as estimated by 
immunohistochemical analysis (P = 0.0025, mixed model analysis of 
variance), suggesting that the fluorescent probe indeed binds c-Met 
in vivo in humans (Fig. 3h).
Histological analysis was possible for 100 of the 101 lesions 
removed; 47 were adenomas, 42 hyperplastic polyps and 11 were 
classified as normal. Twelve (26%) of the adenomas were found on 
the second-pass dual WL/FL examination, of which three were visible 
in WL after closer inspection and nine (19%) were only visible in 
FL. Twelve lesions (nine hyperplastic polyps, three normal) detected 
with WL imaging did not show increased fluorescence; of these only 
three (two hyperplastic polyps, one normal) were not visible in FL 
at all, the rest being visible in the fluorescence images owing to their 
contours. The histological classification of lesions was significantly 
associated with the level of fluorescence seen in them in vivo (Fig. 3g, 
P = 0.00003, Fisher’s exact test). Both imaging modalities were equally 
likely to identify false positive lesions (eight in each modality).
All available biopsies from detected lesions (n = 100), as well as two 
biopsies taken from endoscopically normal 
mucosa from each patient, were analyzed for 












































































































Figure 3 Simultaneous WL and FL images 
of representative lesions of the various 
morphological and histological subtypes found. 
(a–c) The lesions shown are clearly visible in 
WL and show clearly increased fluorescence. 
(d) A lesion that, although it is visible in WL, 
has enhanced visibility in FL. (e,f) Images 
representative of the nine lesions that were only 
visible in FL. Polyps are indicated by the white 
arrows. (a) 2-cm pedunculated (Paris 0-Ip) 
tubular adenoma. (b) 4-cm subpedunculated 
(Paris 0-Ips) tubulovillous adenoma. (c) 2-cm 
sessile (Paris 0-Is) serrated polyp. (d) 5-mm  
flat elevated (Paris 0-IIa) tubular adenoma.  
(e,f) flat (Paris 0-IIb) tubular adenomas, 5 
and 4 mm in diameter, respectively. (g) Graph 
showing the relationship between the degree of 
fluorescence and the histological diagnosis.  
(h) Graph showing the relationship between  
c-Met expression and the degree of 
fluorescence. Error bars are means ± s.e.m.  
n.s., not significant; ***P < 0.001; mixed-
model analysis of variance. (i) Graph showing 
the relationship between c-Met expression  
and histological diagnosis. Error bars are  
means ± s.e.m. n.s., not significant;  
***P < 0.001, mixed-model analysis of variance.
Hyperplastic polyp Serrated adenoma Tubular adenomaNormal colon
Figure 4 c-Met expression analysis by 
immunohistochemistry using an antibody 
specific for the extracellular domain of c-Met. 
(a,b) Normal colonic mucosa. (c,d) Hyperplastic 
polyp. (e,f) Serrated adenoma. (g,h) Tubular 
adenoma. Scale bars (a,c,e,g), 1 mm; (b,d,f,h), 
100 µm. The lower images show the area within 
the red rectangle on the upper images at higher 
magnification. Controls omitting the primary 
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analysis using an antibody specific for the extracellular domain of 
c-Met. Whereas c-Met is expressed in normal colon tissue and is 
evenly expressed along the crypt axis on the epithelial cell membrane, 
it is significantly more highly expressed in both hyperplastic and 
adenomatous polyps (Fig. 3i, P < 0.001 for both, mixed-model 
analysis of variance; and Fig. 4).
Biopsies from detected lesions and normal mucosa from the patient 
study were also analyzed ex vivo for direct fluorescence from the 
probe while embedded in paraffin. There is more fluorescence detect-
able in lesions with abnormal histology (adenomatous or hyper-
plastic) than in normal tissue with a target-to-background ratio of 
2.3 ± 1.1 (mean ± s.d.). Fluorescence microscopy was also performed 
on tissue sections from normal colon and lesions from the patient 
study. Fluorescence immunohistochemistry for c-Met in representa-
tive images from normal colon and from an adenomatous polyp can 
be compared to direct fluorescence from GE-137 in the same sections 
and in the overlay of c-Met immunohistochemical analysis and direct 
fluorescence measurements from GE-137 (Fig. 5). There is clearly 
increased signal from GE-137 in adenomatous tissue, and this overlaps 
with the c-Met expression from the immunohistochemical analyses. 
The direct fluorescence from the probe is less clearly on the cell 
membrane than the c-Met expression from immunohistochemistry. 
We have previously documented that the process of fixation influ-
ences the distribution of fluorescent probes for membrane-bound 
receptors16, so this is likely to be a tissue-fixation artifact.
DISCUSSION
A variety of new endoscopic imaging techniques aimed at enhanc-
ing the ability to detect and characterize colorectal lesions have been 
described17. They can be broadly characterized into either wide-field 
‘red-flag’ techniques or high-resolution ‘optical biopsy’ techniques. 
The latter (confocal laser endomicroscopy, endocytoscopy, and 
optical coherence tomography) are not suitable for lesion detection, 
as they only microscopically examine a few square millimeters of the 
colon at a time.
Wide-field techniques using light alone, such as narrow-band imaging 
(NBI), digital I-scan, Fujinon Intelligent Color Enhancement (FICE), 
and autofluorescence imaging (AFI), are widely used, but there are as 
yet no large randomized trials showing an advantage of these modalities 
over high-definition WL endoscopy for lesion detection18,19.
Topical application of nonspecific dyes has been used both in con-
junction with WL (Methylene blue, indigo carmine) and fluorescence 
endoscopy (hexaminolevulinate)20. An inherent limitation of topical 
application is that complete mucosal coverage is rarely achievable, 
and mucus consistency and bowel cleanliness detrimentally affect 
mucosal binding.
Topical application of fluorescently labeled antibodies has been 
investigated using fluorescein-labeled monoclonal antibodies against 
carcinoembryonic antigen (CEA) and a modified fiber colonoscope 
in humans21, and using i.v. administration of fluorescein-labeled anti-
bodies against epidermal growth factor receptor (EGFR) or Alexa 
Fluor 488–labeled antibodies against vascular endothelial growth 
factor (VEGF) in mice in conjunction with confocal laser endomi-
croscopy22,23. Problems associated with the use of fluorescently 
tagged antibodies include a long clearance half-life after injection and 
concerns regarding immunogenicity24. In this respect, low-molecular-
weight small peptides have a number of potential advantages, such as 
favorable pharmacokinetic and tissue distribution patterns, increased 














anti–c-Met antibody DAPI nuclear stain anti–c-Met/DAPI GE-137 c-Met/GE-137 overlapNo primary antibody
Figure 5 c-Met expression in normal colon and an adenomatous polyp as detected by immunohistochemistry and GE-137. (a,b) Controls omitting the 
primary antibody showed no staining. (c,d) Fluorescence immunohistochemistry for c-Met labeled with fluorescein isothiocyanate (FITC), shown in 
green. (e–h) Nuclei stained with DAPI, shown in blue (e,f), and DAPI combined with immunohistochemistry for c-Met (g,h). (i,j) Direct fluorescence 
microscopy to visualize GE-137, shown in red. (k,l) The overlap between immunohistochemical staining for c-Met and the presence of GE-137, shown 
in yellow. All images are taken from the same tissue sections from biopsies taken after GE-137 administration. (a,e,g,i,k) Normal colonic mucosa. 
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Topical application of a fluorescein-labeled heptapeptide probe 
isolated from a phage library has been investigated in conjunction 
with endoscopic confocal microscopy in humans11. The exact target 
for this heptapeptide has yet to be determined, so any potential down-
stream signaling due to peptide binding has not been evaluated. This 
study made use of endoscopic confocal microscopy, in which only a 
few square millimeters of colon can be examined, and fluorescein, a 
suboptimal fluorophore for use in the colon26.
Further studies of topical application of fluorescent imaging probes 
in the colon in mice include a Cy5.5-conjugated octapeptide probe 
combined with a near-infrared wide-field fiber optic catheter26 and 
an enzymatically activated green fluorescent probe (gGlu-HMRG) 
and a modified bronchoscope27.
Probe-based studies in the human colon have generally used 
either fluorescein or Alexa Fluor 488 as the fluorophore. These 
green fluorescent fluorophores fluoresce maximally at around 
520 nm. Autofluorescence of colonic mucosa also occurs at similar 
wavelengths28. Many authors recommend the use of fluorophores in 
the NIR spectrum, in which colon autofluorescence is negligible26.
In summary, previously investigated techniques have all suffered 
from one or more of potential limitations, including the use of: non-
specific dyes; topically applied dyes or probes for which complete 
mucosal coverage is rarely achievable; antibody probes with potential 
for immunogenicity and unfavorable pharmacokinetics; peptide 
probes with an unknown target and thus potential effects on down-
stream signaling; fluorophores whose fluorescence spectrum overlaps 
with colon autofluorescence; or endoscopy techniques unsuitable for 
wide-area surveillance.
GE-137 is a small (26 amino acids) fluorescently labeled peptide 
agent with high affinity for a known molecular target, human 
c-Met, and with no effect on downstream signaling, conjugated with a 
near-infrared fluorophore. Peptides for the peptide component were 
selected for their ability to bind c-Met without having effects on 
downstream signaling. Fluorophores for the fluorophore component 
were selected to have spectral characteristics that do not overlap with 
colon autofluorescence, as well as to provide minimal photobleach-
ing and maximum brightness. GE-137 was selected from a panel of 
peptide and fluorophore combinations for its optimal combination 
of high affinity for c-Met, minimal binding to plasma proteins and 
a favorable safety profile and pharmacodynamics in animal models. 
These initial studies in humans suggest that GE-137 is safe and may 
enhance visualization of colonic polyps.
One of the frequently stated goals of advanced imaging techniques 
in the colon is the ability to characterize lesions in vivo to avoid the 
added costs and risks associated with the removal of benign hyper-
plastic polyps29. However, the appreciation of the malignant potential 
of serrated polyps makes it important that molecular imaging tech-
niques also detect these lesions30. In this study, we identified 36 
hyperplastic lesions and eight serrated polyps. Most of these were 
visible in fluorescent mode (94% and 100% respectively) and the 
majority (78% and 87% respectively) showed increased fluorescence 
(Supplementary Table 3).
Although several studies confirm c-Met overexpression in CRCs, 
the number of adenomas studied has been small and hyperplastic 
polyps have not been included13,31. We find that c-Met expression 
is significantly increased in both hyperplastic and adenomatous tis-
sue. This confirms that c-Met is a suitable target for the molecular 
detection of colorectal neoplasia.
This study has a number of limitations. The low number of 
patients included in this pilot study precluded randomization 
between WL and fluorescence endoscopy as the first-pass 
endoscopic technique. It is therefore not possible to ascertain 
whether fluorescence endoscopy leads to the detection of substan-
tial numbers of additional polyps. Second, as there are currently no 
commercial fluorescence video colonoscopes that can visualize Cy5, 
a customized fluorescence endoscopy system had to be developed 
especially for this study using a fiber colonoscope. Future studies 
using high-definition fluorescent video colonoscopy, once this is 
available, are needed to confirm the encouraging but preliminary 
findings presented here.
In conclusion, intravenous administration of GE-137 is feasible and 
safe in humans. It accumulates specifically in c-Met–rich premalignant 
lesions and can potentially enhance polyp detection at colonoscopy.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
ACKNoWLeDGMeNTS
The authors would like to acknowledge the contributions of T. Attramadal,  
E. Johannesen and H. Dirven, who were the Project Leaders at GE Healthcare 
in the screening, lead selection and the translational/early clinical phases of the 
project, respectively. GE Healthcare AS received support for the GE-137 project 
from The Research Council of Norway grant no. 192984/BIA and SkatteFUNN 
grant no. 201108. F.W.B.v.L. and T.B. were supported by the The Netherlands 
Organisation for Scientific Research (NWO) VIDI (grant no. STW BGT11272) and 
a Postdoctoral Molecular Imaging Scholarship from the Education and Research 
Foundation for Nuclear Medicine and Molecular Imaging. 
AuTHoR CoNTRIBuTIoNS
J.B., I.M.C.K. and P.B.G. designed the pharmacological studies; B.I., M.S.-N.  
and L.-I.Ø. developed the probe and the drug product; and R.B., R.M.B., S.A.M., 
A.H. and G.T.D. conducted the preclinical testing. L.S. and A.J.K. performed 
recruitment and safety testing for the clinical studies. M.L.d.K. performed the 
statistical analyses. H.M. performed the histopathological analysis of polyps. 
M.V.W. performed the c-Met immunohistochemical analysis. F.W.B.v.L., P.W.V. 
and T.B. performed the ex vivo direct fluorescence imaging studies. A.H., S.Y. and 
G.T. designed the method for assessing the imaging characteristics of the probe 
and developed the colonoscopy system. P.B.G., A.M.J.L. and J.C.H.H. designed the 
clinical studies, A.M.J.L. and J.C.H.H. performed the clinical studies, and  
J.C.H.H. wrote the manuscript. 
CoMPeTING FINANCIAL INTeReSTS
The authors declare competing financial interests: details are available in the online 
version of the paper.
Reprints and permissions information is available online at http://www.nature.com/
reprints/index.html.
1. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69–90 (2011).
2. Atkin, W.S. et al. Once-only flexible sigmoidoscopy screening in prevention 
of colorectal cancer: a multicentre randomised controlled trial. Lancet 375, 
1624–1633 (2010).
3. Baxter, N.N. et al. Association of colonoscopy and death from colorectal cancer. 
Ann. Intern. Med. 150, 1–8 (2009).
4. Brenner, H. et al. Protection from right- and left-sided colorectal neoplasms after 
colonoscopy: population-based study. J. Natl. Cancer Inst. 102, 89–95 (2010).
5. Kaminski, M.F. et al. Quality indicators for colonoscopy and the risk of interval 
cancer. N. Engl. J. Med. 362, 1795–1803 (2010).
6. Kahi, C.J., Hewett, D.G., Norton, D.L., Eckert, G.J. & Rex, D.K. Prevalence and 
variable detection of proximal colon serrated polyps during screening colonoscopy. 
Clin. Gastroenterol. Hepatol. 9, 42–46 (2011).
7. van Rijn, J.C. et al. Polyp miss rate determined by tandem colonoscopy: a systematic 
review. Am. J. Gastroenterol. 101, 343–350 (2006).
8. Clapper, M.L. et al. Detection of colorectal adenomas using a bioactivatable 
probe specific for matrix metalloproteinase activity. Neoplasia 13, 685–691 
(2011).
9. Marten, K. et al. Detection of dysplastic intestinal adenomas using enzyme-sensing 




























t e c h n i c a l  r e p o r t s
nature medicine  VOLUME 21 | NUMBER 8 | AUGUST 2015 961
10. Endlicher, E. et al. Hexaminolevulinate-induced fluorescence endoscopy in patients 
with rectal adenoma and cancer: a pilot study. Gastrointest. Endosc. 60, 449–454 
(2004).
11. Hsiung, P.-L. et al. Detection of colonic dysplasia in vivo using a targeted 
heptapeptide and confocal microendoscopy. Nat. Med. 14, 454–458 (2008).
12. Fearon, E.R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. 
Cell 61, 759–767 (1990).
13. Di Renzo, M.F. et al. Overexpression and amplification of the met/HGF receptor gene 
during the progression of colorectal cancer. Clin. Cancer Res. 1, 147–154 (1995).
14. Nanjappan, A.K.S. et al. Peptides that specifically bind HGF receptor (cMet) and 
uses thereof. Patent no. WO 2004/078778 A2.  (2004).
15. Moestue, S. et al. Whole-body section fluorescence imaging—a novel method for 
tissue distribution studies of fluorescent substances. Contrast Media Mol. Imaging 
4, 73–80 (2009).
16. van den Berg, N.S., Buckle, T., Kuil, J., Wesseling, J. & van Leeuwen, F.W.B. 
Immunohistochemical detection of the CXCR4 expression in tumor tissue using the 
fluorescent peptide antagonist Ac-TZ14011-FITC. Transl. Oncol. 4, 234–240 (2011).
17. Kiesslich, R., Goetz, M., Hoffman, A. & Galle, P.R. New imaging techniques and 
opportunities in endoscopy. Nat. Rev. Gastroenterol. Hepatol. 8, 547–553 (2011).
18. Adler, A. et al. A prospective randomised study on narrow-band imaging versus 
conventional colonoscopy for adenoma detection: does narrow-band imaging induce 
a learning effect? Gut 57, 59–64 (2008).
19. Kuiper, T. et al. Endoscopic trimodal imaging detects colonic neoplasia as well as 
standard video endoscopy. Gastroenterology 140, 1887–1894 (2011).
20. Mayinger, B., Neumann, F., Kastner, C., Haider, T. & Schwab, D. Hexaminolevulinate-
induced fluorescence colonoscopy versus white light endoscopy for diagnosis of 
neoplastic lesions in the colon. Endoscopy 42, 28–33 (2010).
21. Keller, R., Winde, G., Terpe, H.J., Foerster, E.C. & Domschke, W. Fluorescence 
endoscopy using a fluorescein-labeled monoclonal antibody against carcinoembryonic 
antigen in patients with colorectal carcinoma and adenoma. Endoscopy 34, 
801–807 (2002).
22. Foersch, S. et al. Molecular imaging of VEGF in gastrointestinal cancer in vivo 
using confocal laser endomicroscopy. Gut 59, 1046–1055 (2010).
23. Goetz, M. & Wang, T.D. Molecular imaging in gastrointestinal endoscopy. 
Gastroenterology 138, 828–833 (2010).
24. Wu, A.M. & Olafsen, T. Antibodies for molecular imaging of cancer. Cancer J. 14, 
191–197 (2008).
25. Chen, K. & Chen, X. Design and development of molecular imaging probes. 
Curr. Top. Med. Chem. 10, 1227–1236 (2010).
26. Liu, Z., Miller, S.J., Joshi, B.P. & Wang, T.D. In vivo targeting of colonic dysplasia 
on fluorescence endoscopy with near-infrared octapeptide. Gut 62, 395–403 
(2013).
27. Mitsunaga, M. et al. Fluorescence endoscopic detection of murine colitis-associated 
colon cancer by topically applied enzymatically rapid-activatable probe. Gut 62, 
1179–1186 (2013).
28. Imaizumi, K. et al. Dual-wavelength excitation of mucosal autofluorescence for 
precise detection of diminutive colonic adenomas. Gastrointest. Endosc. 75, 
110–117 (2012).
29. Rex, D.K. Reducing costs of colon polyp management. Lancet Oncol. 10, 
1135–1136 (2009).
30. Leggett, B. & Whitehall, V. Role of the serrated pathway in colorectal cancer 
pathogenesis. Gastroenterology 138, 2088–2100 (2010).
31. Wielenga, V.J. et al. Expression of c-Met and heparan-sulfate proteoglycan forms 






























GE-137 safety. In vitro safety testing. GE-137 was tested in vitro in the Ames 
and MLA (mouse lymphoma assay) assays for evaluation of genotoxic hazard, 
the 3T3 NRU (neutral red uptake) assay for assessment of phototoxic hazard, 
the hERG assay for assessment of potential of drug-induced QT interval 
prolongation, and in a proliferation assay for evaluation of interference with 
c-Met signaling.
Animal safety testing. GE-137 has no or very low affinity for mouse c-Met 
and approximately 100-fold lower affinity for dog c-Met compared to human 
c-Met. The reported amino acid sequence homology for c-Met from mouse, 
rat, dog and Macaca fascicularis (cynomolgus monkey) is approximately 
89.5%, 88.1%, 91.0% and 98.2%, respectively, when compared to human 
c-Met. The cynomolgus monkey was selected as the relevant non-rodent 
species for safety studies.
General toxicity of GE-137 Injection was evaluated in an expanded acute 
single-dose toxicity study in male and female rats. The nonclinical safety 
studies in cynomolgus monkey were conducted in compliance with the Animal 
Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the 
Office of Laboratory Animal Welfare (USA) under a protocol reviewed and 
approved by the Preclinical Study Review Team, Global Biology, GE Healthcare. 
The nonclinical safety study in the rat were conducted in compliance with the 
Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, 
and the Office of Laboratory Animal Welfare (USA) under a protocol 
reviewed and approved by the Preclinical Study Review Team, Global Biology, 
GE Healthcare. Animals received injections of up to 50 times the expected 
maximum clinical dose (0.36 mg/kg body weight) scaled for body surface area 
and were observed up to 4 weeks afterwards. In a 14-day repeat-dose toxicity 
study in sexually mature cynomolgus monkeys (4 to 9 years of age for males 
and 3–7 years of age for females). The high dose-group in this study received 
daily doses of 16.8 mg GE-137 per kg of body weight. As part of the study, the 
genotoxic risk of GE-137 injection was assessed in the micronucleus test of 
peripheral blood. In addition, a spermatogenic staging evaluation of the testes 
and epididymis was carried out to assess the potential adverse effects on the 
male reproductive system. Animals were monitored up to 4 weeks after the 
last administered dose.
The potential of GE-137 injection to cause effects on the cardiovascular 
system was assessed in the conscious male cynomolgus monkey in doses up 
to 48 mg/kg of body weight. Changes in ECG, blood pressure and heart rate 
were assessed. When the NOAEL was expressed as human equivalent dose 
based on body surface area, this corresponds to 15.5 mg/kg body weight of 
GE-137. The 14C-biodistribution studies in rats and cynomolgus monkeys 
indicated that GE-137 does not cross the blood–brain barrier. The effect of GE-
137 injection on the central nervous system was tested in the modified Irwin 
screen in the male rat with injection of up to 48 mg GE-137 per mg/kg of body 
weight. The effects of GE-137 injection on respiratory function as indicated by 
tidal volume, respiration rate, and minute volume were also assessed in 
the male rat in a head-out plethysmography study with doses up to 48 mg 
GE-137 per mg/kg of body weight.
Studies in mouse xenografts. Animal models. The use of the mice was approved 
by the Norwegian Animal Research Authority (NARA) (Forsøksdyrutvalget). 
No formal statistical analysis was performed to estimate sample size. The 
animals were not formally randomized to a particular intervention. Female 
BALB/c/A nude (Bom) mice were housed in individually ventilated cages 
(IVC, Scanbur BK) with HEPA filtered air with ad libitum access to ‘Rat and 
Mouse nr. 3 Breeding’ diet (Scanbur BK).
Two colon cancer cell lines were used, HCT-15 and HT29, both derived 
from human colon carcinomas and acquired directly from the ATCC 
(Manassas, VA). HCT-15 cells: ATCC (CCL-225). HT-29 cells: ATCC 
(HTB-38). The cell lines were authenticated by STR profiling and tested 
for mycoplasma contamination by the ATTC before delivery.
The two cancer cell lines have different expression levels of the target cMet. 
One relatively high (HT29, termed ‘high expression tumor’) and the other 
relatively low (HCT-15, termed ‘low expression tumor’). cMet expression levels 
were determined via by ELISA in both tumor types. The cell lines are tumori-
genic when inoculated subcutaneously into nude mice. Cells were grown and 
prepared for subcutaneous inoculation in RPMI (Sigma, cat. no. R0883) with 
10% serum and penicillin/streptomycin.
Stocks were made at passage number four (P4) and frozen down for storage 
in liquid nitrogen at 2 × 107 cells per vial in the culture media containing 5% 
DMSO. On the day of the transplantation, the cells were thawed quickly in a 
37 °C water bath (~2 min), washed and resuspended in PBS (centrifugation 
at 2,000 r.p.m. for 10 min). Thorough mixing of cells in the vials was ensured 
every time cells were aspirated into the dosing syringe. Volumes of 0.1 ml 
of cell suspension were injected subcutaneously (s.c.) over the shoulder and 
back using a fine-bore needle (25 G) while the animals were under light gas 
anesthesia. The animals were then returned to their cages and the tumors were 
allowed to grow for 13–17 d. The animals were allowed an acclimatization 
period of at least 5 d before the inoculation procedure.
Quantitative biodistribution of contrast agent and negative control in 
tumor-bearing BALB c/A nude mice. Whole blood sampled from the vena 
cava, ~0.7 ml per animal, was centrifuged for preparation of samples for 
plasma analysis, whereas organs were collected, snap frozen and stored at 
−80 °C until the day of analysis. Liver and kidneys were homogenized in PBS 
(0.4 g ml−1) using a Polytron homogenizer. Tumor and muscle were crushed 
in liquid nitrogen, buffer with detergent was added (RIPA buffer, Santa Cruz), 
followed by homogenization using a Dounce glass homogenizer. For prepara-
tion of standard curve samples, blood plasma and homogenized tissue were 
spiked with known amounts of substance in a relevant concentration range. 
Standard curves were then generated for each organ based on fluorescence 
intensity measurements using a Fluoroskan Ascent FL fluorescence plate 
reader (Thermo Labs) at 646-nm excitation/678-nm emission. The concen-
tration of fluorescence reporter in the test samples were calculated on the 
basis of the standard curves.
Fluorescence scanning of whole mouse cryosections. Euthanized mice were 
frozen slowly in liquid nitrogen and stored at −70 °C. The frozen animals 
were embedded in a 2% carboxymethylcellulose (CMC) block, cut into 75-µm 
sections and freeze dried for 12–16 h. The sections were scanned in fluores-
cence mode using a Fujifilm FLA5100 fluorescence scanner with a 635-nm 
laser/665-nm long-pass filter.
In vivo animal imaging. An epifluorescence small-animal imaging system 
was employed, comprised of a 12-bit cooled charge-coupled device (CCD) 
camera, with a 660-nm laser source providing the excitation light. The animals 
were placed inside a box that prevents ambient light from disturbing the imag-
ing procedure. Pharmacokinetic data was produced by acquiring one image 
frame every 30 s for 2 h (acquired with WASABI imaging software, Hamamatsu, 
Japan) from the time of contrast agent administration. For immobilization dur-
ing the kinetics optical imaging procedure, the animals were anaesthetized in a 
coaxial open mask to light surgical level anesthesia with Isoflurane in a oxygen:
nitrous oxide carrier gas. The animals were supplied with external heating 
from a heating blanket to sustain normal body temperature for the duration 
of the imaging. A Venflon catheter was placed into the tail vein for contrast 
agent administration. Each animal was given one contrast agent injection. The 
images were analyzed using custom-made MATLAB software (Mathworks), 
and were quantified in terms of raw target to background and signal to noise 
ratios and contrast enhancement dynamics. Image formation consists of sub-
traction of a calibrated camera bias from the raw CCD image data. The light 
source employed was inhomogeneous over the field of view, being of stronger 
illumination in the center of the image. In order to avoid illumination bias in 
the image a ‘flat field’ calibration of a uniformly reflecting object was used to 
normalize the fluorescence image. Washout kinetics for the contrast agent and 
negative control were estimated from the fluorescence time-intensity curves 
for regions of interest placed over the tumor and adjacent skin. The imaging 
time point for the targeting experiments was estimated as the time when the 
fluorescence signal from the contrast agent in the background or skin was 
approximately at the same level (~2 times) as the native fluorescence from the 
animal. Animals received the contrast agent (or negative control) intravenously 
at a dose of 50 nmol kg−1 body weight and were killed and imaged at the time 
point indicated from the kinetics measurement.
Competition. Excess of the unlabeled targeting peptide (180 or 650 
times molar excess) was administered in a volume of 0.25 ml i.v. 5 min 





























contrast agent in order to evaluate the effects of competition for the target. 
Experiments were performed in the high expression tumor type. Quantitative 
biodistribution was determined in blood, muscle, liver and tumor, as well 
as in vivo imaging in the mouse model mock-up of the clinical imaging 
conditions described below.
Mouse model mock-up of clinical imaging conditions. Imaging system. 
The imaging system used was built around a clinical laparoscope (model 
Hopkins II, S/N 26003 AA, Karl Storz, Germany). The laparoscope offers 
superior resolution to a fiberscope but was adjusted to produce the same 
spatial resolution as provided by a fiberscope. A 100-mW 635-nm diode 
laser was used as the excitation light source and fluorescence emission filters 
placed between the eyepiece and the CCD detector. The laser was mounted 
in the temperature stabilized laser mount and controlled by the laser driver 
and TEC (Thermoelectric cooling) controller. The laser light was passed 
through a mechanical shutter (Shutter controller: model SC10, ThorLabs; 
Shutter: model SH05, ThorLabsbefore entry into the liquid light guide (Light 
guide: model 495NB, Karl Storz, Germany). The fluorescence filters used were 
Omega Optical 3D filters with a long pass and band pass stacked together 
(660ALP/50 part no. 3012211 and 680AF40/50 part no. 3012209, Omega 
Optical, Brattleboro, VT). The CCD detector was a Hamamatsu ORCA-ERG 
(Hamamatsu Photonics, Japan), a progressive scan interline CCD with micro 
lens and IEEE 1394 FireWire interface. The effective number of pixels was 
1344(H) × 1024(V). The pixel clock rate was 14.75 MHz/pixel with 16 frames 
per second at 2 × 2 binning. The r.m.s. readout noise is 8 electrons, a full 
well capacity of 18,000 electrons and 2,250:1 dynamic range. The chip can 
be cooled with forced air Peltier cooling to −30 °C. The dark current was 
0.03 electrons/pixel/s. Readout was digitized to a nominal 12 bits. The 
quantum efficiency at 700 nm was ~50%.
Experimental procedure. The imaging probes were injected i.v. into the 
lateral tail vein and the animals were killed immediately before imaging. 
The optimal imaging time point was estimated previously from imaging phar-
macokinetics studies (not reported here), with the same strain of mice. For 
each animal the subcutaneously grown tumors were excised post mortem. 
Tumor slices 1.6 mm thick and 3–4 mm in diameter were placed on top of a 
2- cm cleaned and longitudinally opened section of colon. The animal was 
then imaged with the imaging system.
Imaging system parameters. The spatial resolution of the images was set to 
correspond to a low spatial resolution similar to that afforded by a fiber-based 
implementation (~32,000 pixels in the image field of view). A field of view 
of 4.44-cm diameter was selected, giving an image area of 15.5 cm2. With 
32,000 pixels covering the field of view, the pixel area is 0.0484 mm2 with 
linear pixel dimension (square pixel) of 220 µm. The distance of the object 
from the endoscope tip was adjusted (to 9 cm) to provide the desired field of 
view from the laparoscope. The −6 dB intensity level of the excitation laser 
light from the endoscope was used to define the dimension of the field of 
view. The camera binning was 2 × 2 with 0 on chip gain. The above settings 
(spatial resolution and field of view) correspond to those expected in a clinical 
system. An exposure time of 10 s was calculated to match the expected clinical 
illumination conditions.
Image artifact reduction. A piece of black card was placed directly 
above the kidney and bladder areas as necessary, to shield the kidney 
and/or bladder from excitation light and prevent artifact arising from the 
high fluorescence signal from the kidneys and bladder. This is not expected 
to be an issue in clinical imaging due to the greater distance separating tissues 
(in humans). Fecal material is also fluorescent. This is removed by flushing 
the opened section of colon. However, fecal material may be present in other 
parts of the intestine. This was confirmed by imaging with an excitation light 
wavelength that does not excite fluorescence from the dye, but still causes 
feces to fluoresce.
Target-to-background ratio. Two regions of interest (ROIs) covering the 
tumor slice and relevant colon background tissue were drawn manually 
(all regions defined by the same operator) with reference to the printed images 
annotated at the time of data acquisition. The mean and s.d. were calculated 
from pixels falling inside the region boundaries. Target-to-background ratios 
were calculated from these processed regions (mean signal from tumor ROI 
divided by mean signal from background ROI).
ROC analysis. A receiver operating characteristic (ROC) analysis was per-
formed in order to quantify the efficacy of the compound in the animal model. 
This involves visually assessing images with the tumor both present and absent. 
The images are pre-processed before the visual assessment. It is important 
to use standardized image formation and presentation procedures for image 
interpretation. Standardized and automated image formation algorithms and 
presentation procedures were adopted.
Image pre-processing. There are four steps in the image formation process. 1. 
Removal of camera bias by producing an image with the shutter closed 
with the same exposure time and read out rate used for animal image data 
collection. This background level is subtracted from the raw CCD camera 
data from the animal image. 2. Correction for illumination inhomogeneity: 
the illumination light is not homogenous, but it produces an illumination 
with a Gaussian-like profile. An image is acquired from a uniform target 
(stack of white paper), placed at the same distance from the laparoscope as 
the animal. This image is then used to normalize the fluorescence image in 
order to compensate for the illumination light inhomogeneity. The tumor 
piece is often placed centrally in the image, where the light is stronger (and 
hence the tumor will look relatively brighter). The normalization removes 
this bias. 3. Median filtering for noise reduction: the images contain noise. 
The noise content is dominated by photon (shot) noise. This arises due to 
the low light levels used to form the fluorescence image. A median filter with 
a 3 × 3 kernel is applied for noise reduction. 4. Interpolation to reduce 
pixelation: the displayed image appears pixelated due to the relatively large 
pixel dimension. The pixelated appearance is reduced by 2 × 2 interpolation 
using a cubic b-spline interpolant.
Visual scoring. A standard visual scoring system employed for ROC analysis 
was used to assess the images. Assessors were required to score their assess-
ment of the presence of a tumor section by giving a score from 1 to 5 where 
1 = definitely absent, 2 = probably absent, 3 = possibly present, 4 = probably 
present and 5 = definitely present.
There were two data sets for ROC analysis. Both data sets had a positive 
disease group (image of tumor slice placed on the colon), and a negative group 
(no tumor slice present). The first data set comprised of 18 animals given the 
imaging agent at a nominal dose of 1 nmole per animal and imaged 120 min 
after administration (positive group). The negative group had 16 images, with 
a total of 34 images in the first data group. The second data set was extended 
with additional animals that received a lower (one-third) dose, and animals 
imaged at additional time points as part of the dose and time point study. The 
second data set positive group (n = 39) was comprised of the 18 animals in the 
first data set positive group, plus additional images obtained from a dosing 
study (0.3 nmole per animal) and additional time point images (60 min and 
240 min). The negative control group (n = 52) comprised the 16 images for 
the first group, plus additional images at the dose and times corresponding 
to the additional images from the positive group. Images obtained with the 
negative control substance (scrambled targeting sequence) were also included. 
There were 52 images in the negative group, giving a total of 91 images for 
the second data set.
Instructions to visual scorers. Prior to the visual scoring session the following 
instructions were provided for the scorers:
•  There are 91 fluorescence images of open mouse colons to be scored.
•  The extent of the opened colon section is given by the green line.
•  The tumor is expected to provide positive contrast (appearing bright).
•  There are one or zero tumor slices present in the image.
Images are from 1-nmole and 0.3-nmole doses (50 and 17 nmol kg−1  
body weight).
The standard scoring scale was presented, along with expected image 
examples (from a different image data set to that being scored), in order to 
indicate the expected range. In addition native fluorescence images acquired 
with green light excitation were also available in some instances where they 
identified obvious artifacts from fecal material. Scorers were blinded as to 
which treatment group the images belonged.
Image presentation. Images were presented in random order and scored by 
five observers who provided a consensus score. Images were also randomly 





























Human subjects. Healthy volunteers were recruited from the CHDR (Centre 
for Human Drug Research) volunteer database. In addition, study-specific 
advertisements placed in local media and internet advertisements were used. 
15 subjects at high risk of colorectal neoplasia were recruited by staff at the 
Gastrointestinal Department of Leiden University Medical Center. Subjects 
gave written acknowledgment of informed consent after receiving oral and 
written explanation of the study. A medical screening took place after they 
had consented to participate. After approval by the subjects, their general 
practitioners were notified when the subject was included in the study. The trial 
was registered in the EudraCT database (EudraCT number: 2010-019197-33). 
Please see Supplementary Methods for inclusion and exclusion criteria.
GE-137 safety testing in humans. The safety and tolerability of four ascend-
ing doses (0.02, 0.04, 0.09, and 0.18 mg kg−1 of body weight) of GE-137 were 
evaluated in 20 healthy volunteers enrolled into 4 dose groups, each containing 
five subjects. In each group, four healthy volunteers received GE-137 injec-
tion and one received placebo (NaCl 0.9%) given intravenously by slow bolus 
injection. Healthy volunteers all underwent four sigmoidoscopy examinations 
without sedation after previous full bowel preparation, at 1, 2, 3 and 4 h post-
injection. A further 15 subjects at high risk of colorectal neoplasia received 
0.13 mg GE-137 per kg of body weight GE-137 and underwent a full colon-
oscopy 3 h after injection.
Human safety monitoring. At times indicated in Supplementary Table 4, 
venous blood samples and urine samples were obtained for clinical laboratory 
tests, for screening and safety monitoring purposes, and for antibody testing 
and pharmokinetic analyses. Samples were analyzed by the Central Clinical 
Laboratories of Leiden University Medical Center. The following assessments 
were performed: Hematology: hemoglobin, hematocrit, red cell count (RBC), 
MCV, MCH, MCHC, total white cell count (WBC), leukocyte differential 
count and platelet count. Biochemistry: sodium, potassium, calcium, chloride, 
total protein, albumin, glucose, urea, creatinine, creatinine phosphokinase 
(CPK), total bilirubin (total, conjugated), alkaline phosphatase, AST, ALT, 
gamma-GT and LDH. Coagulation: activated partial thromboplastin time 
and prothrombin time. Virology: hepatitis B, C and HIV serology (healthy 
volunteer study only). Urinalysis: leucocytes, blood, nitrite, protein, bilirubin, 
urobilinogen, pH, specific gravity, ketone and glucose (Multistix 10 SG (Bayer, 
Mijdrecht, the Netherlands) Urinary drug screen: cocaine, amphetamines, 
morphine, benzodiazepines, methadone and THC (healthy volunteers only). 
Urinary pregnancy test: CARDS O.S. H.C.G.-urine test kits (Pacific Biotech, 
Inc., San Diego, CA, USA). All female subjects underwent a pregnancy test 
unless they were surgically sterile or post-menopausal.
Additional safety measurements. Vital signs. Blood pressures and heart rate 
were measured using a Nihon-Kohden BSM-1101K monitor (Nihon-Kohden, 
Japan). Body temperature was measured tympanically with a BRAUN digital 
clinical thermometer (BRAUN Corporation, Germany).
Electrocardiogram. Standard 12-lead electrocardiographs were made using 
Nihon-Kohden Cardiofax (Nihon-Kohden, Tokyo, Japan). The following param-
eters were reported: PR-, QRS-, QT-, QTc- interval and heart rate. QT correction 
for heart rate was done using the Bazett formula. Continuous 1 lead ECG was 
performed from 5 min before IMP/placebo administration until 15 min after 
administration (using Nihon-Kohden BSM-1101K monitor, Tokyo, Japan).
GE-137 concentration measurement. Blood samples were collected using vac-
uum tubes containing sodium citrate as an anticoagulant (Becton Dickinson, 
NJ, USA). Samples were kept at 4 °C, centrifuged within 2 h of collection (at 
2,000g at 4 °C for 10 min), and plasma was split into two equal aliquots and 
stored at −80 °C until analysis. 100 µl of plasma, 20 µl of the internal standard 
(AH112959 (GE internal compound)) and 600 µl of ice-cold precipitation 
solution (acetonitrile:water:CHAPS, (2:1:0.01, vol/vol/wt) were vortex-mixed 
for 30 s and then centrifuged for 15 min at 10,000g at 6 °C. The superna-
tants (~650 µl) were transferred to glass vials and dried under nitrogen. The 
dried extracts were dissolved in 100 µl of 12.5 mM ammonium acetate and 
25 µl from each sample was injected into a HPLC system (HP Agilent 1100 
HPLC, CA, USA) and the compounds separated on an XBridge Shield R18 
column, 3.5 µm particle size (Waters, MA, USA), using a 25 mM ammonium 
acetate/acetonitrile gradient run at 0.3 ml min−1. Column temperature was 
35 °C. After separation, GE-137 and the internal standard were detected by a 
UV-visible detector set at 650 nm.
The calibration standards were prepared daily by diluting different amounts 
of standard solutions of GE-137 with human plasma in a range from 0.01 to 
10.2 µg GE-137 ml−1. Prior to analysis the calibration standards were spiked 
with the internal standard and treated similar to the human plasma samples. 
The calibration curves were made from the calibration standards by plotting 
the peak area ratio of GE-137 to the internal standard against the theoretical 
concentration of GE-137. The curve was fitted to a second order polynomial 
equation y = a + bx + cx2 with a weighing factor 1/y2. The amount of GE-137 
in the samples was determined by calculating the same peak area ratio as 
above and correlating this ratio to µg/ml plasma GE-137 using the calibra-
tion curve. Chromeleon version 6.6 (Dionex, CA, USA) was used for data 
sampling, integration, preparation of calibration curves and concentration 
determinations.
Colon wall fluorescence signal. From preclinical imaging studies, the optimal 
imaging time point was estimated to be approximately when the background 
fluorescence-imaging signal has cleared to one-half of its peak value. The back-
ground fluorescence washout time was calculated from serial measurement of 
colon wall fluorescence over time in healthy volunteers using two methods. 
In the contact method, the tip of the endoscope was placed gently on the 
surface of the colon wall, the endoscope light source was set to a standardized 
setting and eight images at non-overlapping locations in the distal part of the 
colon at each time point were recorded. In the reference standard method, a 
series of reference standards with calibrated fluorescence and optical proper-
ties were used. The reference standards consisted of titanium dioxide and iron 
oxide particles, to match the colon wall scattering and absorption coefficients 
respectively, and a small quantity of quantum dots for fluorescence, embedded 
in biocompatible epoxy resin. Reference standards inserted via the endoscope 
were temporarily held against the colon wall during imaging to provide a local 
fluorescence reference target. Again, eight images were recorded with the refer-
ence standard at different non-overlapping locations in the distal part of the 
colon at each time point. ROIs were positioned in the background tissue and 
the fluorescence reference standard for all snapshots at each time point. For 
each ROI, the mean and standard error of the fluorescence signal intensity in 
each pixel were calculated. Subsequently, mean and standard error were cal-
culated and plotted at each time point. For contact measurements, the mean 
of the image signal intensity of the whole image was calculated. Subsequently, 
mean and standard error were calculated and plotted at each time point.
Optimal imaging dose and optimal imaging time point estimation. In the 
preclinical imaging studies the best achievable target-to-background ratio of 
a lesion was approximately 1.5:1. To achieve this ratio within a practical time-
frame the optimal dose and optimal time interval between GE-137 administra-
tion and endoscopy were estimated to be 0.18 mg kg−1 ( = estimated clinical 
dose; ECD) and 2 h respectively. (A higher dose will give a greater signal, but 
will require longer for wash-out from the background.)
To assess whether these results translated to humans, the fluorescent 
reference standards scaled to the dose-levels were used during the sigmoido-
scopies conducted in the healthy volunteer. The reference standards provided a 
calibrated fluorescence target which could be used to compare relative fluores-
cence levels from adjacent structures and compare the fluorescence intensity 
to the preclinical models. The fluorescence levels were designed to provide a 
TBR of approximately 1:1 at one hour p.i. and corresponded to the expected 
fluorescence level in a lesion containing c-Met at 2 to 3 h after injection.
It was expected that the time taken for the reference standard TBR to change 
during sequential sigmoidoscopies from 1:1 to 1.5:1 would provide an estimate 
of the time needed to wait for sufficient background clearance for efficacy. 
This was approximately 2 h 40 min for dose groups 3 (0.09 mg kg−1) and 
4 (0.18 mg kg−1). The imaging efficacy was deemed sub-optimal for the two 
lowest doses. The results from dose groups 3 and 4 were consistent with 
the contact measurement washout half-time, and indicated that optimal 





























It was agreed that the longest wait after injection that was practical for study 
logistics was ~3 h. The dose of 0.09 mg kg−1 showed optimal efficacy at 3 h. 
It was expected that the colonoscopy exam in patients could take an hour. 
During this time the contrast agent would continue to wash out. To select the 
lowest possible dose while ensuring that good contrast was maintained for up 
to 1 h after the start of colonoscopy, a correction was applied to compensate 
for the washout. The washout was measured to be 10−0.12 × time and therefore 







Therefore, an optimal imaging time of 3 h after injection, and an optimal 
imaging dose of 0.7 times ECD (0.13 mg kg−1) was recommended for use in 
the pilot study in patients.
Pilot study in patients at high risk of colorectal neoplasia. In 15 patients, 
a single i.v. dose of 0.13 mg kg−1 GE-137 was administered, based on the 
results of preliminary assessments in the healthy volunteers. Colonoscopy was 
performed at 3 h after injection. A single experienced endoscopist (J.C.H.H.) 
performed all the endoscopies. For the patient study the colonoscope was 
first inserted to the cecum using WL only. The colonoscope was then with-
drawn while examining for possible neoplasia with each colonic segment 
being examined twice. The first-pass examination was performed using WL 
only. On detecting a lesion with WL, location in the colon, size, visibility in 
WL and the Paris classification were noted. Lesion visibility was classified 
as either ‘visible lesion’ or ‘normal flat mucosa’. The lesion was then further 
examined for visibility in FL and its fluorescence characteristics were noted 
before biopsy. Fluorescence was related to background fluorescence and 
categorized as follows: clearly increased, mildly increased or same fluorescence 
as background. The endoscope was reinserted and a second-pass examination 
of the same colonic segment performed with combined FL and WL endoscopy. 
A large WL and smaller FL image were displayed simultaneously on the same 
monitor. Characteristics of lesions detected on the second pass were noted 
before biopsy.
Decisions regarding classifications in WL and FL were reached by consen-
sus by the endoscopist and the endoscopy assistant during the procedure. As 
lesions could be visible in FL based on contours independent of their level of 
fluorescence, visibility of lesions in FL was assessed after the study day had 
taken place using the video images that were made during the procedure.
Lesion morphology was described according to the Paris classification and 
was based on the real-time imaging and snapshot data. Decisions on lesion 
classification based on review of the images were reached by consensus after 
assessment by two independent investigators (J.C.H.H. and A.M.J.L.). Size (in 
mm) was estimated using open biopsy forceps (8 mm) held next to the lesion.
Fluorescence colonoscopy system. A commercial high-resolution video 
colonoscope was not available to provide simultaneous real-time imaging of 
WL and GE-137 emission fluorescence. The requirement of highly sensitive 
detection of fluorescence, as well as full flexibility of imaging parameters, 
necessitated the development of a custom instrument. To ensure patient safety, 
the instrument combines a custom image head mounted on the proximal end 
of a clinically approved lower GI fiber colonoscope (Pentax, FC-38LV) and 
medical grade components are incorporated where possible. The combined 
instrument has been tested for safety by an independent medical device testing 
and certification company (Intertek).
In addition to the commercial colonoscope, the system is comprised of 
an illumination module and an imaging head (Supplementary Fig. 6). The 
illumination module consists of a 150-W halogen lamp (Pentax LH-150PC) 
for WL and a high power (3-W) laser diode source (Modulight, ML1496) 
centered at 635 ± 3 nm coupled into a 600-µm diameter multimode fiber 
(Thorlabs, M29L01). The laser output power is restricted to Class 3B opera-
tion by limiting the light emitted from any accessible apertures to less 
than 500 mW. The laser drive current is adjusted such that an irradiance 
of ~10 mW cm−2 is achieved at a working distance of 25 mm from the 
distal tip of the colonoscope.
The WL source and laser are filtered with a short-pass filter at 650 nm 
(Semrock FF01-650/SP-25) and a laser line excitation filter (Semrock, FF01-
628/40-25), respectively, before combining through a dichroic beam splitter 
(Omega Optical, 615DRSP.) The combined light is mated to the colonoscope 
illumination port through a custom mechanical adaptor and focused onto the 
ball lens of the port using an aspheric condenser lens (Thorlabs, AL2520-A).
The imaging head, mounted on the proximal end of the scope, consists of 
cameras, filters, and imaging optics. Light emerging from the proximal end 
of the colonoscope passes through a dichroic beamsplitter (Semrock, FF660-
Di02-25x36), separating the WL and fluorescence components into separate 
beam paths. The individual beams are imaged onto independent cameras using 
a 30-mm achromatic relay lens (Thorlabs, AC254-030-A1-ML) The lens focal 
length and diameter were chosen to minimize vignetting of the image.
To maximize sensitivity, fluorescence is filtered with an emission filter 
(Semrock FF01-692/40-25) to filter out wavelengths outside 672–712 nm and 
detected with a monochrome Peltier-cooled (to −20 °C) electron multiplying 
charge coupled device (EMCCD, Retriever Technology RT-XMV-247.) The 
camera pixel count is 658(H) by 496(V), running at eight frames per second 
(8 f.p.s.) and a 94-ms exposure time. For WL video, a color camera is used 
(Sentech, STC-CLC152A) with 1392(H) by 1040(V) pixels running at 8 fps 
and a 40-ms exposure time. To avoid excessive leakage of the red excitation 
laser into the WL channel, a laser rejection (notch) filter (Semrock, NF03-
633E-25) is placed in front of the color camera. The entire imaging head is 
mounted in a metal housing (Rittal, JB080804HC), which serves as a heat 
sink for passive cooling of the cameras. The metal housing is attached to the 
medical cart (Endocart, ED-100B) via an articulated support arm (Bretford, 
FPSMWADJ2XXAL) that ergonomically supports the weight of the imaging 
head yet provides six degrees of freedom for the required range of motion.
Images are acquired via a single-board, dual-channel frame grabber with 
CameraLink interface (Matrox Imaging, Solios eCL SOL-6M-CL-E), using 
custom image-acquisition software programmed in Microsoft Visual Studio 
2005 and Matrox Imaging Library (MIL) version 9.0. The computer system 
consists of a workstation (Hewlett Packard, xw8600) running 32-bit Windows 
XP and two 24-inch monitors (Hewlett Packard, LP2475w) one of which is 
mounted on a support arm (Endocart, EDS-305) and the other on a satellite 
medical cart (Endocart, EMS-104).
The raw video streams are directly recorded to RAID0 drives in AVI file 
format. During live image acquisition, video streams from both channels are 
digitally filtered with a finite impulse response (FIR) filter to remove the fiber 
honeycomb pattern. FIR kernel sizes up to 9 × 9 pixels may be implemented 
without appreciable delays on display and recording frame rates. Following 
each procedure, data is archived to a 1 TB external drive (Western Digital 
WDE1UBK10000N). Electrical isolation of the entire imaging system is 
achieved with a medical-grade isolation transformer (Tripp Lite IS1800HG) 
with up to an 1800-W capacity (Supplementary Fig. 6).
Histopathology. All biopsies were formalin fixed, paraffin embedded, 
sectioned, and stained with H&E according to the standard protocol of 
Leiden University Medical Center. Final histological evaluation was performed 
by a single specialist GI pathologist (H.M.). For further analysis all diagnoses 
were grouped into three basic categories according to the WHO classifi-
cation of tumors of the digestive system: normal, hyperplastic polyps and 
adenomatous polyps.
Immunohistochemical analysis of c-Met expression. 4-µm sections were 
deparaffinized, rehydrated and heat treated (100 °C) in Dako Cytomation 
Retrieval Buffer pH 9.0 (Dako, Glostrup, Denmark) for 12 min using the 
Biogenex microwave EZ Retriever (Biogenex, Fremont, CA). Slides were 
then immersed in 3% hydrogen peroxide solution for 10 min, blocked with 
Serum-Free Protein Block for 20 min and then incubated for 60 min with a 
primary rabbit monoclonal antibody specific for the N terminus of human 
c-Met (antibody EP1454Y, Abcam, Cambridge, UK) at room temperature at 
a concentration of 1:150 using the i6000 Infinity automated staining system 
(Biogenex, Fremont, CA). Slides were subsequently incubated with HRP- 
conjugated goat anti-rabbit IgG for 30 min at room temperature, antibody 





























counterstained with hematoxylin. Positive control sections known to be c-Met 
positive and a buffer negative staining control in which the primary antibody 
was omitted and replaced with the primary antibody diluent were included 
for each staining run.
Analysis of slides to ascertain the extent and intensity of c-Met staining 
took place at Pathology Diagnostics Ltd., Cambridge, UK. A board-certified 
anatomic pathologist determined the score for each section by visual assess-
ment of 10 fields of view (FOV) at 40× magnification using light microscopy. 
All stained slides had been relabeled and were assessed in a blinded fashion. 
The c-Met staining intensity of the epithelial cell membrane was evaluated 
for each FOV using a four-point scale of 0 (no staining), 1 (weak staining), 
2 (moderate staining) and 3 (strong staining). The percentage area occupied 
by epithelial cells was determined for each FOV by image analysis 
using Image Pro Plus software (Media Cybernetics, US). The percentage 
area occupied by epithelial cells per FOV was multiplied by the epithelial 
cell membrane staining intensity in the same FOV to reach a score (0-300 
arbitrary units) for each FOV. The final score for each slide was the calculated 
mean for the 10 FOV.
Fluorescence immunohistochemistry. 4-µm sections were deparaffinized, 
rehydrated and incubated overnight at 4 °C with c-Met monoclonal rabbit 
primary antibody (Abcam, EP1454Y, ab51067) diluted 1:100 in PBS. Sections 
were then in incubated with Alexa Fluor 488–goat anti-rabbit IgG (Invitrogen) 
diluted 1:100 PBS for 1 h at room temperature and mounted with SlowFade 
Gold Antifade Reagent with DAPI (Invitrogen). Sections were analyzed with 
a Leica DM5500 B fluorescence microscope (Leica Microsystems) using Cy5, 
FITC and DAPI filter settings and dual-color overlay images were made using 
ImageJ software. Control sections in which the primary antibody was omitted 
were performed with each separate experiment. Control images were taken 
using identical settings to those used for sections where primary antibodies 
were used.
Ex-vivo fluorescence measurements of tissue blocks. Fluorescent signals 
in formalin-fixed, paraffin-embedded tissue blocks each containing a single 
biopsy taken from endoscopically normal colon or lesions seen at colonos-
copy from the patient study were measured for all specimens using an IVIS 
Spectrum scanner (Xenogen, San Francisco, CA, USA) as we have performed 
previously32. Tissue blocks were analyzed using Cy.5 settings (excitation 
640 nm, emission 680 nm). Fluorescence intensities (photons sec−1 cm−2) were 
calculated using Living Image software (Xenogen). The target-to-background 
ratio was calculated by dividing the fluorescent intensity in tissue samples 
from lesions with abnormal histology (adenomatous or hyperplastic) by the 
fluorescence intensity in healthy control tissue samples of the same patient.
Statistical analyses. A contingency table for the histology groups and the 
categories of fluorescence was analyzed for association with a Fisher’s exact 
test. As the 130 biopsies were analyzed from 15 patients and most patients 
had biopsies with a fluorescence level in all three fluorescence categories and 
a histological diagnosis in all (grouped) categories, within subject comparisons 
seemed appropriate for the analysis of the association between c-Met expres-
sion and fluorescence levels and c-Met expression and histological diagnosis. 
The analysis was performed with a mixed model analysis of variance with 
‘fixed factor’ fluorescence category or grouped diagnosis and ‘random factor’ 
subject with a variance components covariance structure. Averaging the 
c-Met expression within subject and category was not necessary for the 
analysis to be feasible. The following ‘contrasts’ were calculated within 
the model: mildly increased fluorescence versus the same fluorescence as 
background; clearly increased fluorescence versus the same fluorescence 
as background; clearly increased fluorescence versus mildly increased fluo-
rescence. The analysis was repeated with ‘fixed factor’ grouped diagnosis and 
the following ‘contrasts’ were calculated: hyperplastic polyp versus normal; 
adenomatous lesion versus normal; hyperplastic polyp versus adenomatous 
lesion. Data were shown as least-square means with 95% confidence intervals 
as error bars. All calculations were performed using SAS for windows V9.1.3 
(SAS Institute, Inc., Cary, NC, USA).
Ethics. The protocol of the studies in humans was approved by the Medical 
Ethics Committee of Leiden University Medical Center. The CCMO (Central 
Committee on Research involving Human Subjects) acted as the Competent 
Authority. The study was conducted according to the Dutch Act on Medical 
Research involving Human Subjects (WMO).
Additional methods. Detailed methodology is described in the Supplementary 
Methods.
32. van der Poel, H.G., Buckle, T., Brouwer, O.R., Valdes Olmos, R.A. & van Leeuwen, F.W.  
Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in 
prostate cancer patients: clinical proof of concept of an integrated functional 
imaging approach using a multimodal tracer. Eur. Urol. 60, 826–833 (2011).
np
g
©
 2
01
5 
N
at
ur
e 
A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
